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Toward novel antirejection strategies: In vivo immunosuppressive
properties of CTLA4Ig. Allograft rejection is a process that depends on T
cell receptor-ligand interaction and costimulatory signals generated when
accessory molecules binds to their ligands, such as CD28 to the B7
molecules. We investigated the possibility that B7 blockade in vivo by the
soluble CD28 receptor homolog CTLA4Ig modulates rejection process in
a rat model of kidney allograft. Lewis rats orthotopically transplanted with
MHC incompatible kidney from Brown-Norway rats were given an
intraperitoneal injection of CTLA4Ig (0.2 or 0.5 mg/day) or a nonspecific
immunoglobulin for seven days, starting the day of transplant. While
control rats rejected the graft within 10 days, all animals given CTLA4Ig
had a prolonged kidney allograft survival, independently from the dose of
the fusion protein employed. Actually, at the dose of 0.2 mg/day kidney
grafts survived 36 to 50 days (median 44 days), while with the highest dose
graft survival was 40 to 60 days (median 50 days). In all CTLA4Ig-treated
rats renal grafts were well functioning as documented by serum creatinine
concentrations comparable to age- and sex-matched control rats 30 days
after transplant. At this time in Vitro mixed lymphocyte culture (MLR)
experiments showed a significant reduction of proliferation of peripheral
blood lymphocytes from CTLA4Ig-treated rats when challenged with BN
but not third party Wistar Furth lymphocytes. We have also shown that
combining a short course of CTLA4Ig (0.2 mg/day) with a dose of
cyclosporine (C5A) low enough to fail to inhibit graft rejection allowed
indefinite engraftment of kidney allograft without the need of continuous
immunosuppression. In these animals the in vitro MLR proliferative
response to BN donor lymphocytes was significantly reduced as compared
to controls. These findings show that long-term unresponsiveness to
kidney allograft can be achieved even with a short course of combined
administration of CTLA4Ig with low dose CsA at least in rats.
Primary immunologic rejection of vascularized organs is medi-
ated by binding of histocompatibility alloantigen to T cell receptor
(TCR) via direct and direct recognition pathway [1, 2]. Engage-
ment of TCR with alloantigen is followed by T cell activation and
proliferation mediated by specific signals delivered through the
TCR/CD3 complex on the cell surface of T-lymphocyte [1]. Many
recent studies however have documented that TCR stimulation
alone is not enough to sustain full activation of T cell clones and
that additional signals are required [3, 4]. It has been documented
that such additional signals are delivered through accessory
molecules [5—10] of which one, called CD28, has been recently
identified on the surface of resting peripheral T cells [11]. CD28,
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a member of the immunoglobulin gene superfamily, modulates a
signal transduction pathway independent from TCR-stimulation
that synergizes with the latter in promoting T cell activation and
subsequent proliferation and differentiation [11, 12]. Cloning and
expression studies have established that CD28 is a 44 kDa
homodimer T cell-specific glycoprotein that binds to a B cell
activation antigen initially called B7/BB-1 [11]. Originally identi-
fied as a single ligand for the CD28 activation pathway [13], more
recently an additional B7-related gene encoding for a new B7
receptor (termed B7-2, while the original is now referred as B7-1
molecule) has been isolated [14, 15]. There is also evidence for the
existence of another ligand, tentatively identified as B7-3 [16].
B7-1 and B7-2, both members of the Ig gene superfamily, have
similar organization of extracellular domains while the cytosolic
one is markedly different as indicated by comparison of the
predicted amino acid sequences [17—19]. The mechanism by which
CD28 stimulation upon binding to its specific ligand contributes to
T cell activation is likely by enhancing interleukin-2 transcription
by mechanism(s) that remain to be identified [7, 11, 12, 20].
The gene encoding for CD28 shares high identity with a closely
related gene termed CTLA-4, which possesses a similar genomic
organization [21—23]. Recently a soluble chimeric protein,
CTLA4Ig, has been obtained by the fusion of the variable domain
of the human CTLA-4 gene with the CH2 and CH3 domains of
the human IgGi constant region [24—27]. Soluble CTLA4Ig binds
with high efficiency to mouse [28] and rat [29] B7-1 and B7-2
ligand [30j, thus acting as CD28 receptor homolog.
The availability of the above molecule for studies in vivo has
opened the exciting possibility to develop more specific strategies
to prevent graft rejection. Molecules that inhibit the interaction of
CD28 with its ligands B7-11B7-2 would impair selectively the
function of those T-lymphocyte clones activated by transplant
specific antigens, thus avoiding the risks associated with the
non-selective major immunosuppressants currently in use that
include an increased frequency of infections and malignancies.
Findings that a short course of CTLA4Ig treatment induced
long-term human pancreatic islet survival in mice [28] and pro-
longed cardiac allograft survival in rats [29] suggested that we
investigate whether costimulatosy signals through CD28 to anti-
gen-specific T cell proliferation are indispensable to sustain
rejection in a rat renal allograft model, and provide further
insights on the potential mechanism(s) by which CTLA4Ig treat-
ment would prolong renal allograft survival. Moreover, since in
the above published work such treatment did not allow permanent
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cardiac engraftment, we evaluated whether combining a short
course of CTLA4Ig and low dose cyclosporine (CsA) induced
permanent acceptance of a renal allograft.
Methods
Studies were conducted on male Lewis (RT11) and Brown-
Norway (RT1) rats (Charles River, Calco, Italy) with initial
weights of 200 to 250 g body weight. Animal care and treatment
were conducted in conformity with the institutional guidelines
that are in compliance with national and international laws and
policies (EEC Council Directive 86/609, OJL 358, Dec. 1987; NIH
Guide for the care and use of laboratory animals, NIH Publication
No. 85-23, 1985). All animals were allowed free access to standard
rat chow (containing 20% of proteins by weight) and drinking
water.
Experimental design
To evaluate the effect of B7 blockade by the soluble CD28
receptor homolog CTLA4Ig on allograft survival, MHC-incom-
patible Brown-Norway (RT1) rat kidneys were orthotopically
transplanted into Lewis (RT11) rat recipients by microsurgery
technique [31]. After transplant all animals were kept in individ-
ual metabolic cages for collection of 24-hour urine samples and
monitoring of graft survival. Survival time of the renal graft was
defined as the time from transplantation to the development of
anuria. Moreover, blood samples were collected from the tail vein
for measurement of serum creatinine concentration before, at the
time of development of anuria, or at different time of the
follow-up. Two groups of Lewis rats were considered in which
CTLA4Ig was given intraperitoneally for seven days at the daily
dose of 0.5 mg (N = 6) or 0.2 mg (N = 6), respectively, beginning
two hours before kidney transplant. As controls additional trans-
planted rats (N = 5) were given a nonspecific rat immunoglobulin
intraperitoneally (IgG 0.5 mg/day) as a daily administration. The
dose of CTLAIg was chosen on the basis of previous published
works [29].
Moreover, in order to determine the functional status of
alloreactive T cells of transplanted animals on CTLA4Ig, periph-
eral blood lymphocytes from surviving recipients of Brown-
Norway (BN) kidney allografts were tested for their ability to
proliferate to BN in the standard one-way mixed lymphocyte
response (MLR) assay. As a control, MLR response to the third
party lymphocytes taken from Wistar Furth rat was performed.
In additional experiments we investigated whether CTLA4Ig
(0.5 mg/day, N = 4) or the nonspecific immunoglobulin (0.5
mg/day, N = 3) treatment modified the number of lymphocytes in
the peripheral blood. This has been performed at the end of the
seven day treatment and 30 days after transplantation in animals
with preserved graft renal function. To evaluate whether in the
same CTLA4Ig-treated rats peripheral T cells were functionally
inactivated or anergic, in vitro MLR was performed in the
presence of interleukin-2 (rIL-2, 50 U/well) [32].
Since in an heart transplant model it has been previously shown
that CTLA4Ig itself was not tolerogenic [29], we then investigated
whether a state of unresponsiveness to kidney allograft could
occur combining treatment with the soluble chimeric protein and
low dose CsA. To this purpose three additional groups of Lewis
rats were orthotopically transplanted with Brown-Norway rat
kidneys and given CsA alone (2 mg/kg/day p.os for 14 days, N =
3), or CTLA4Ig alone (0.2 mg/day i.p. for 7 days, N = 4), or the
combination of the two treatments (N = 6) for the same period.
This low dose of CsA was chosen according to previous observa-
tions showing that this treatment failed to prevent kidney allograft
rejection in rats [33]. Graft survival and serum creatinine concen-
tration were monitored as above. MLR response to Brown-
Norway donor or third party Wistar-Furth lymphocytes was
determined in tolerant animals. At the same time the in vitro
response to (rIL-2) was also investigated.
Kidney transplantation
Rat renal transplants were performed as previously described
[31]. Ether anesthesia was used throughout. In the donor, the left
kidney was carefully removed by first dissecting the ureter from
the surrounding fat, avoiding injury to the blood supply, and
transecting the ureter near the bladder junction. The renal artery
was then separated from the renal vein near the aorta, and
ligatures were placed around the aorta and inferior vena cava
above and below the left artery and vein. The aorta was cut
between the ties, thereby leaving a segment with the renal artery.
The aortic segment was made into a Carrel patch. The kidney was
then placed in cold saline before transplantation. In the recipient,
left nephrectomy was performed. The renal artery was ligated,
and a clamp was placed on the renal vein near the inferior vena
cava. End-to-end renal venous anastomosis was performed first,
and the clamp on the renal vein was removed. The renal artery
was then anastomosed to the aorta with the small patch of donor
aorta and by clamping the aorta distal to the renal vein with two
clamps. The ureter was pulled through the posterior wall of the
dome of the bladder, which was first opened from the front. A
stitch of 7-0 silk was passed from the outside through the bladder
wall and through one wall of the ureter and to the outside of the
bladder again. The stitch was tied outside of the bladder, and the
bladder was then closed. The right kidney of the recipient was
then removed. Vascular anastomoses were made with 7-0 silk.
Ischemic time ranged from 20 to 30 minutes (mean 25 mm).
Mixed lymphocyte response (MLR) assay
Peripheral blood lymphocytes were isolated from peripheral
blood of responder Lewis and stimulator BN or third party WF
rats by Ficoll-Hypaque density gradient centrifugation, and sus-
pended in RPMI 1640 medium (GIBCO, Grand Island, NY,
USA) supplemented with L-glutamine (2 mM), penicillin (100
U/mi), streptomycin (100 g/ml), and 10% fetal calf serum. The
MLR was set up by culturing equal number of Lewis responder
cells and irradiated (3000 Rads) BN or third party WF stimulator
cells in 96-well U bottom plates at 37°C with 5% CO2 for four
days. Proliferation was assayed by 3H-thymidine uptake as previ-
ously described [34]. Relative response was calculated as experi-
mental minus background counts per minute divided by control
minus background counts per minute.
Other analysis
The CD4 T-lymphocyte subset present in the peripheral blood
of Lewis transplanted rats was measured by flow cytometty
analysis as previously described [29, 35]. Cells were stained with
primary mouse anti-rat antibody and counterstained with fluores-
cein isothiocyanate-conjugate goat anti-mouse antibody. Cells
were analyzed by a FACScan (Becton Dickinson). Renal function
was assessed by measuring serum creatinine values. Blood was
obtained by tail vein puncture and then by leaving the collected
Perico et al: CTLA4Ig as a novel antirejection strate 243
Graft survival Median
days
CTLA4Ig 0.2 mg/day 36, 40, 43, 45, 47, 50 44
CTLA4Ig 0.5 mg/day 40, 48, 50, 50, 55, 60 50
Ig 0.5 mg/day 8, 8, 9, 10, 10 9
blood samples at 37°C for 30 minutes. The sera were frozen and
kept at —20°C until assayed. Serum creatinine levels were deter-
mined by the alkaline picrate method [361.
Statistical analysis
Results are expressed as mean SD. Data were analyzed by
t-test or by one-way analysis of variance (repeated measures with
Fisher's protected least significant difference, Scheffé's F test, and
Dunnett's test for multiple comparisons, as appropriate. Statisti-
cal significance level was defined as P < 0.05.
Results
Effect of short course CTLA4Ig on graft survival
Table 1 shows survival of the grafts in control or CTLA4Ig-
treated rats. While control Lewis recipients given a nonspecific
immunoglobulin had a sudden decline in renal function and
rejected their renal allograft within 8 to 10 days, recipients Lewis
rats given for seven days CTLA4Ig at the dose of 0.2 mg/day had
a markedly prolonged survival (up to 50 days). Lewis recipients
that were given for the same period of time an higher dose of
CTLA4Ig had their graft surviving for up to 60 days (all individual
data for these experiments are given in Table 1).
In all kidney recipients, urine formation occurred soon after
transplantation, indicating an immediate recovery of renal func-
tion. Diuresis started to fall at days six to eight with complete
anuria 8 to 10 days after transplantation in control rats, while it
was maintained for the following 30 days observation period in
animals given 0,2 or 0.5 mg/day CTLA4Ig (0.2 mg/day CTLA4Ig
18 4 ml/24 hr; 0.5 mg/day CTLA4Ig 22 6 ml/24 hr). These
animals became anuric between day 36 to 50 and 40 to 60,
respectively.
Figure 1 depicts renal function, as serum creatinine concentra-
tion, in controls and CTLA4Ig-treated rats. In transplanted
control animals serum creatinine values were elevated at the time
of progressive development of oliguria (3.06 0.19 mg/dl).
CTLA4Ig-treated rats (0.2 and 0.5 mg/day) maintained a normal
renal function for all the 30 post-transplant days, as documented
by serum creatinine values (0.2 mg/day CTLA4Ig 0.63 0.08; 0.5
mg/day CTLA4Ig 0.60 0.05 mg/dl). Thereafter in all these
animals graft failure was associated with elevated serum creati-
nine values (0.2 mg/day CTLA4Ig 3.22 0.15 mg/dl; 0.5 mg/day
CTLA4Ig 3.09 0.12 mg/dl, at the time of development of
oliguria). At day 30 after transplantation in all surviving animals
body weight and food intake values were in the range of sex- and
age-matched control animals, and overall the rats were in good
health.
At the same time point, systemic unresponsiveness induced by
seven day administration of CTLA4Ig was established by evalu-
ating the functional status of T cells on the MLR in vitro.
MLR cpm
LewXBN LewXWF
CTLA4Ig 0.2 mg/day 4899 862° 15840 2364
CTLA4Ig 0.5 mg/day 4735 703 16150 2870
Values are mean SD.
Control MLR proliferative response of lymphocytes from untreated
Lew against BN cells (cpm: 16330 3540).
Control MLR response of lymphocytes from untreated Lew against WF
cells (15750 2250 cpm).
Background MLR in the absence of alloantigen is 215 30 cpm.
Control MLR of lymphocytes from untreated Lew X BN against BN
cells is 15230 3200 cpm.
a P < 0.01 vs. untreated controls and Lew X WF
Peripheral blood lymphocytes from CTLA4Ig-treated rats showed
significantly (P < 0.01) lower MLR proliferation as compared to
untreated controls (Table 2). The relative response of LEW >< BN
one way MLR was on average 30% in renal transplanted rats
given CTLA4Ig, while untreated control LEW X BN MLR was
100%. By contrast, the proliferative response of these animal's
lymphocyte to the third party Wistar Furth rat was equivalent to
control (97%). The decline in MLR proliferation response was
reversed in vitro by coincubating the lymphocyte mixture with
rIL-2. This occurred with lymphocytes obtained during CTLA4Ig
(0.5 mg/day) administration (day 7, cpm 14,320 2870) and 23
days after CTLA4Ig withdrawal (cpm, 16,860 3580). Control
MLRs for untreated LEW cells stimulated with BN lymphocytes
were 15,720 2480 cpm (day 7) and 15,970 3840 cpm (day 23),
respectively.
CTLA4Ig administration did not reduce the number of CD4
lymphocytes in the peripheral blood. Thus at the end of the seven
day treatment with 0.5 mg/day CTLA4Ig the CD4 lymphocytes
were 2,920 92/mm3, a value comparable to those in animals
given the nonspecific immunoglobulin (3015 121/mm3). Simi-
larly 30 days after transplantation the CD4 lymphocyte count in
the blood was 3,115 106/mm3.
Table 1. Effect of 7 day intraperitoneal administration of different
doses of CTLA4Ig or nonspecific immunoglobulin on survival of Brown-






Basal Day 8—i 0 Day 30 Day 36—60
Fig. 1. Time-course of renal fhnction in Lewis rats receiving a kidney
allografi and treated with different doses of CTLA4Ig or nonspecific immu-
noglobulin for 7 days. Values are mean so. < 0.01 vs. basal and the
other groups at the same time point. Symbols are: (0) CTLA4Ig 0.2
mg/day; () CTLA4Ig 0.5 mg/day; () Ig 0.5 mg/day.
Table 2. Proliferative response of lymphocytes from CTLA4Ig-treated
Lewis rats when challenged with Brown-Norway or third party Wistar
Furth cells
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Table 3. Effect of combined administration of low dose CsA and




CsA 6, 6, 7 6.5
CTLA4Ig 36, 40, 45, 50 42.5
CTLA4Ig + CsA >75, >75, >76, >76, >79, >79 >76
Effect of combined low dose CsA with CTLA4Ig
Table 3 shows renal graft survival in Lewis recipients given CsA
alone, CTLA4Ig alone, or the combination of the two treatments.
Lewis rats given CsA alone had a sudden decline in renal function
four to six days after transplant and invariably rejected the kidney
within seven days. Lewis rats receiving a short course of CTLA4Ig
(0.2 mg/day) showed a prolonged but not indefinite survival of the
incompatible kidney allograft. Thus in these animals the renal
graft failed within 36 to 50 days. By contrast, the combined
administration of CsA and CTLA4Ig for the same time intervals
allowed indefinite survival of kidney allograft (median survival
time: >76 days). All these animals are still in good health.
In animals given CsA alone diuresis progressively failed from
day 4 and they became anuric between days 6 and 7. Similarly, in
CTLA4Ig-treated rats urine output started to decline at days 32 to
45 with complete anuria 36 to 50 days after transplantation. In
contrast, at day 70 post-transplant in CsA plus CTLA4Ig-treated
animals urine output was well preserved and averaged 17 6
ml/24 hr.
CsA-treated rats developed renal failure, as documented by
elevated serum creatinine values at the time of progressive
development of oliguria (3.06 0.19 mgldl). In the CTLA4Ig-
treated animals a normal renal function was maintained up to 30
days post-transplant (Sr 0.63 0.06 mgldl). However, in these
animals the serum creatinine concentration was elevated when
they became oliguric (3.15 0.27 mgldl). By contrast, in
CTLA4Ig plus CsA group renal function was normal for the entire
observation period (day 70 Sr 0.68 0.08 mg/dl).
In animals with long-term unresponsiveness, performed 70 days
after transplant, the in vitro MLR proliferative response to BN
donor lymphocytes was significantly reduced as compared to
controls (cpm 4350 720 vs. 14,540 1,750). By contrast, the
MLR proliferation to third party Wistar Furth lymphocytes was
comparable to controls (cpm 14,128 2,154). In addition, the
reduction of proliferation was reversed in vitro by rIL-2 (50U/well,
cpm 12,280 3,272).
Discussion
The results of the present study indicate that CTLA4Ig—a
recombinant fusion protein that specifically binds the CD28
ligands B7-1 and B7-2 [24—27, 30}—given for seven days at the
dose of 0.2 mg/day as the sole immunosuppressive therapy,
considerably prolonged rat renal allograft survival (that is, up to
50 days). For comparison all control animals rejected the kidney
within 11 days. There was a numerical tendency for animals given
a higher dose of the chimeric protein (0.5 mg/day) to have a more
prolonged survival of the graft, but the difference did not reach
statistical significant values.
These results could be interpreted as a possible evidence that
the binding of CD28 to its ligands B7-1 and B7-2 in vivo is a crucial
costimulatory step for alloantigen-mediated T cell immune re-
sponse. That this could indeed be the case is supported by in vitro
data that exposure of T cell clones to specific alloantigens was
followed by a state of T cell anergy unless a costimulatosy signal
was provided [37]. On the other hand, stimulation of CD28
molecule in association with a submitogenic dose of anti-CD3
antibody potently induced T cell proliferation [37].
The present findings that B7-1/B7-2 blockade by the CD28
receptor homolog CTLA4Ig prolonged renal allograft survival
represents the in vivo evidence that the process of renal allograft
rejection requires specific costimulatory signals delivered through
CD28 that add to signals transduced via T cell receptor. This
extends to kidney allograft a previous observation in rats with
cardiac transplant given a short-course CTLA4Ig [29]. It is
conceivable from the present results that only the synergic inter-
action of the two pathways would lead to full T cell activation and
proliferation upon challenge of the T cells with renal transplant
antigens. Seven days of CTLA4Ig treatment, despite the dramatic
improvement in graft survival, was not enough to induce perma-
nent tolerance and animals eventually rejected the graft 36 to 60
days after transplantation. A possible interpretation of these data
is that CTLA4Ig by blocking CD28/B7 interaction promotes a
state of clonal T cell anergy as a consequence of the functional
impairment of the co-stimulatory pathway that occurs during the
seven day treatment. Previous in vitro studies have documented
that CTLA4Ig blocks the primary immune response to alloantigen
between Lewis rats and Brown Norway rats, and an almost
complete inhibition of the proliferative response was observed at
concentration of 1 .tg/ml [29]. The latter is further strong evidence
that at least in vitro alloreactive T cell proliferation requires
binding of CD28 to B7.
That CD28 stimulation can serve as an indispensable pathway
to optimally stimulate T cell proliferation, derives from additional
studies we have performed on the functional status of T-lympho-
cytes of CTLA4Ig-treated rats. Indeed one-way mixed lymphocyte
culture experiments showed a marked and significant reduction in
the proliferative response of T-lymphocytes taken from CTLA4Ig
recipients to Brown-Norway lymphocyte challenge. The possibility
that the early phase of unresponsiveness is mediated by functional
peripheral T cell inactivation or anergy is supported by present
findings that rIL-2 added in vitro restored the proliferative re-
sponse of peripheral blood lymphocytes from transplanted Lewis
rats with normal renal function in mixed lymphocyte reaction
assay. On the other hand, evidence has also been provided here
that CTLA4Ig treatment did not reduce peripheral blood CD4
lymphocyte count, indicating that the treatment inactivate the
effector T cell function essential for cell proliferation. A short
course of CTLA4Ig, however, failed to induce permanent engraft-
ment. This is consistent with the possibility that newly formed T
cells released in the circulation after the end of the treatment are
likely functionally intact and do support normal B7-mediated T
cell proliferation. However, the earlier experiments in the cardiac
allograft model showing that thymectomy performed three days
before transplant in animals given a short-course of CTLA4Ig did
not affect graft survival [29], would exclude such a possibility.
Alternatively, seven days of CTLA4Ig may not anergize those T
cells that do not encounter donor antigens during the treatment
period.
T cell proliferation mediated by CD28 involves a series of
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intracellular events distinct from those that initiate cell prolifer-
ation throughout the T cell receptor [6]. Unlike the former the
latter pathway is inhibited by CsA through binding to cyclophilin
and blockade of the phosphatase activity of the calcineurin, which
activates promoters of the IL-2 gene [381. Evidence is also
available that CsA does not affect up-regulation of IL-2 mRNA
that follows CD28-mediated T cell stimulation [39].
We have shown here that combining a short course of CTL4AIg
with a dose of CsA low enough to fail to inhibit graft rejection
allowed indefinite engraftment of kidney allograft without the
need of continuous immunosuppression. This state of unrespon-
siveness to the graft reflects the functional inactivation of periph-
eral T cell, as documented by a permanently reduced proliferative
response to donor cells in in vitro mixed lymphocyte reaction
assays, that is overwhelmed by application to exogenous IL-2 to
the culure mixture.
In conclusion, the present data document that the rejection of
renal allograft in the rat can be effectively inhibited by blocking
the interaction of CD28 with its specific B7 counterreceptors. This
is a strong demonstration in vivo that renal allograft rejection is
the final result of the synergistic action of multiple signal pathways
that add to MHC-associated TCR-mediated signals to promote T
cell proliferation. On the other hand, the demonstration that
permanent graft survival was reached using CTLA4Ig and low
dose cyclosporine indicates novel possible strategy to prolong the
survival of kidney transplants in humans which could be achieved
in the near future by combining classical immunosuppressants
with molecules that block the B7 receptor, and provides a
potential alternative for reducing CsA renal toxicity [40].
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